Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov-Dec;13(11-12):4415-21.
doi: 10.1111/j.1582-4934.2009.00704.x. Epub 2009 Feb 17.

Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1alpha, tumour necrosis factor-alpha and transforming growth factor-beta

Affiliations

Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1alpha, tumour necrosis factor-alpha and transforming growth factor-beta

Rudolf Jarai et al. J Cell Mol Med. 2009 Nov-Dec.

Abstract

B-type natriuretic peptide (BNP) is a cardiac hormone, which plays a major role in body fluid and cardiovascular homeostasis. Produced by cardiac ventricles, its expression is highly regulated by various mediators. Canine cardiac fibroblasts have been identified as a source of BNP. Cardiac fibroblasts are key regulators of myocardial structure and function. We treated cultured human adult cardiac fibroblasts (HACF) with 2000 U/ml tumour necrosis factor-alpha (TNF-alpha), 200 U/ml interleukin-1alpha (IL-1alpha) or 50 ng/ml transforming growth factor-beta (TGF-beta) in the presence or absence of 500 nM fluvastatin. N-terminal pro-BNP (Nt-proBNP) concentration was determined by a competitive enzyme immunoassay. RealTime polymerase chain reaction (real-time PCR) was performed to investigate changes in BNP mRNA expression. Nt-proBNP peptide was present in the conditioned media of HACF and incubation with fluvastatin significantly reduced Nt-proBNP peptide levels. Treatment of HACF with TNF-alpha, IL-1alpha or TGF-beta significantly increased Nt-proBNP levels compared with untreated cells. This effect was completely abolished in the presence of fluvastatin. Real-time PCR analysis confirmed these changes at the level of mRNA expression. Our data suggest that cardiac fibroblasts are a potential source of BNP in the human heart. Pro-inflammatory cytokines, associated with ventricular dysfunction and cardiac fibrosis, seem to be major inducers of BNP production in cardiac fibroblasts. This effect can be reverted by a statin. Based on our data, we speculate that elevated plasma BNP levels might not only reflect increased myocardial stretch but also inflammatory and remodelling processes. A possible benefit of statin-induced reduction in BNP production requires further studies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of IL-1α, TNF-α, TGF-β, IL-6, IL-11, OSM and LIF on proBNP production in HACF and HACM. Confluent monolayers of HACF (open bars) were incubated for 24 hrs with or without 2, 20 and 200 U/ml IL-1α; 20, 200 and 2000 U/ml TNF-α; or 0.5, 5 and 50 ng/ml TGF-β, respectively (panel A). Confluent monolayers of HACM (hatched bars) were incubated for 24 hrs with or without 200 U/ml IL-1α; or 2000 U/ml TNF-α (panel A). Confluent monolayers of HACF were incubated for 24 hrs with or without 100 ng/ml IL-6; 100 ng/ml IL-11; 10,000 U/ml LIF; or 100 ng/ml OSM, respectively (panel B). Nt-proBNP was determined in conditioned media using a specific ELISA and values are given in fmol/ml and represent mean values ± S.D. of three independent determinations. Experiments were performed three times with cells isolated from three different donors. A representative experiment is shown. ***P < 0.001, **P < 0.005, *P < 0.05 as compared with untreated control cells.
Figure 1
Figure 1
Effect of IL-1α, TNF-α, TGF-β, IL-6, IL-11, OSM and LIF on proBNP production in HACF and HACM. Confluent monolayers of HACF (open bars) were incubated for 24 hrs with or without 2, 20 and 200 U/ml IL-1α; 20, 200 and 2000 U/ml TNF-α; or 0.5, 5 and 50 ng/ml TGF-β, respectively (panel A). Confluent monolayers of HACM (hatched bars) were incubated for 24 hrs with or without 200 U/ml IL-1α; or 2000 U/ml TNF-α (panel A). Confluent monolayers of HACF were incubated for 24 hrs with or without 100 ng/ml IL-6; 100 ng/ml IL-11; 10,000 U/ml LIF; or 100 ng/ml OSM, respectively (panel B). Nt-proBNP was determined in conditioned media using a specific ELISA and values are given in fmol/ml and represent mean values ± S.D. of three independent determinations. Experiments were performed three times with cells isolated from three different donors. A representative experiment is shown. ***P < 0.001, **P < 0.005, *P < 0.05 as compared with untreated control cells.
Figure 2
Figure 2
Effect of TNF-α, IL-1α, TGF-β and fluvastatin on proBNP production in HACF. Confluent monolayers of HACF were incubated for 24 hrs without (panel A) or with 200 U/ml IL-1α (panel B), 2000 U/ml TNF-α (panel C) or 50 ng/ml TGF-β (panel D), respectively, in the absence (open bars) or presence of 500 nM, 100 nM, 10 nM or 1 nM fluvastatin without or with 100 μM mevalonate or 10 μM GGPP (hatched bars). In panel E, confluent monolayers of HACF were pre-treated with medium (open bars) or 5 μM Y27632 (hatched bars) for 1 hr and then incubated for 24 hrs without or with 200 U/ml IL-1α, 2000 U/ml TNF-α or 50 ng/ml TGF-β, respectively. Nt-proBNP was determined in conditioned media using a specific ELISA and values are given in fmol/ml and represent mean values ± S.D. of three independent determinations. Experiments were performed 3 times with cells isolated from three different donors. A representative experiment is shown. **P < 0.001, *P < 0.05 as compared with untreated control cells; P¤ < 0.001 as compared with cells incubated without fluvastatin or Y27632.
Figure 2
Figure 2
Effect of TNF-α, IL-1α, TGF-β and fluvastatin on proBNP production in HACF. Confluent monolayers of HACF were incubated for 24 hrs without (panel A) or with 200 U/ml IL-1α (panel B), 2000 U/ml TNF-α (panel C) or 50 ng/ml TGF-β (panel D), respectively, in the absence (open bars) or presence of 500 nM, 100 nM, 10 nM or 1 nM fluvastatin without or with 100 μM mevalonate or 10 μM GGPP (hatched bars). In panel E, confluent monolayers of HACF were pre-treated with medium (open bars) or 5 μM Y27632 (hatched bars) for 1 hr and then incubated for 24 hrs without or with 200 U/ml IL-1α, 2000 U/ml TNF-α or 50 ng/ml TGF-β, respectively. Nt-proBNP was determined in conditioned media using a specific ELISA and values are given in fmol/ml and represent mean values ± S.D. of three independent determinations. Experiments were performed 3 times with cells isolated from three different donors. A representative experiment is shown. **P < 0.001, *P < 0.05 as compared with untreated control cells; P¤ < 0.001 as compared with cells incubated without fluvastatin or Y27632.
Figure 2
Figure 2
Effect of TNF-α, IL-1α, TGF-β and fluvastatin on proBNP production in HACF. Confluent monolayers of HACF were incubated for 24 hrs without (panel A) or with 200 U/ml IL-1α (panel B), 2000 U/ml TNF-α (panel C) or 50 ng/ml TGF-β (panel D), respectively, in the absence (open bars) or presence of 500 nM, 100 nM, 10 nM or 1 nM fluvastatin without or with 100 μM mevalonate or 10 μM GGPP (hatched bars). In panel E, confluent monolayers of HACF were pre-treated with medium (open bars) or 5 μM Y27632 (hatched bars) for 1 hr and then incubated for 24 hrs without or with 200 U/ml IL-1α, 2000 U/ml TNF-α or 50 ng/ml TGF-β, respectively. Nt-proBNP was determined in conditioned media using a specific ELISA and values are given in fmol/ml and represent mean values ± S.D. of three independent determinations. Experiments were performed 3 times with cells isolated from three different donors. A representative experiment is shown. **P < 0.001, *P < 0.05 as compared with untreated control cells; P¤ < 0.001 as compared with cells incubated without fluvastatin or Y27632.
Figure 2
Figure 2
Effect of TNF-α, IL-1α, TGF-β and fluvastatin on proBNP production in HACF. Confluent monolayers of HACF were incubated for 24 hrs without (panel A) or with 200 U/ml IL-1α (panel B), 2000 U/ml TNF-α (panel C) or 50 ng/ml TGF-β (panel D), respectively, in the absence (open bars) or presence of 500 nM, 100 nM, 10 nM or 1 nM fluvastatin without or with 100 μM mevalonate or 10 μM GGPP (hatched bars). In panel E, confluent monolayers of HACF were pre-treated with medium (open bars) or 5 μM Y27632 (hatched bars) for 1 hr and then incubated for 24 hrs without or with 200 U/ml IL-1α, 2000 U/ml TNF-α or 50 ng/ml TGF-β, respectively. Nt-proBNP was determined in conditioned media using a specific ELISA and values are given in fmol/ml and represent mean values ± S.D. of three independent determinations. Experiments were performed 3 times with cells isolated from three different donors. A representative experiment is shown. **P < 0.001, *P < 0.05 as compared with untreated control cells; P¤ < 0.001 as compared with cells incubated without fluvastatin or Y27632.
Figure 2
Figure 2
Effect of TNF-α, IL-1α, TGF-β and fluvastatin on proBNP production in HACF. Confluent monolayers of HACF were incubated for 24 hrs without (panel A) or with 200 U/ml IL-1α (panel B), 2000 U/ml TNF-α (panel C) or 50 ng/ml TGF-β (panel D), respectively, in the absence (open bars) or presence of 500 nM, 100 nM, 10 nM or 1 nM fluvastatin without or with 100 μM mevalonate or 10 μM GGPP (hatched bars). In panel E, confluent monolayers of HACF were pre-treated with medium (open bars) or 5 μM Y27632 (hatched bars) for 1 hr and then incubated for 24 hrs without or with 200 U/ml IL-1α, 2000 U/ml TNF-α or 50 ng/ml TGF-β, respectively. Nt-proBNP was determined in conditioned media using a specific ELISA and values are given in fmol/ml and represent mean values ± S.D. of three independent determinations. Experiments were performed 3 times with cells isolated from three different donors. A representative experiment is shown. **P < 0.001, *P < 0.05 as compared with untreated control cells; P¤ < 0.001 as compared with cells incubated without fluvastatin or Y27632.

Similar articles

Cited by

References

    1. Jarai R, Wojta J, Huber K. Circulating B-type natriuretic peptides in patients with acute coronary syndromes. Pathophysiological, prognostical and therapeutical considerations. Thromb Haemost. 2005;94:926–32. - PubMed
    1. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004;6:257–60. - PubMed
    1. Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002;91:1127–34. - PubMed
    1. Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res. 2002;91:1103–13. - PubMed
    1. Bradham WS, Moe G, Wendt KA, et al. TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol. 2002;282:H1288–95. - PubMed

Publication types

MeSH terms